📈 Jumpstart Signal Watchlist — July 10, 2026

🏢 What they do: BlackBerry Limited provides secure software and services for governments, enterprises, and automakers. Its main products include cybersecurity and endpoint management software, secure communications and crisis-response tools, and QNX embedded software for vehicles and other connected systems.
- 🎯 Current $10.97 is 14% below 3yr high $12.81 · ⏳ SMA200 $5.09 (current price $10.97 is above) · 💰 Market Cap $6.4B
- BB shows decent technicals supported by positive sentiment.

💎 Quality (Q): 46/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 600% (>20%); Revenue growth 52% (>15%); Low LT D/E 0.26 (<1.0); PEG ratio 0.20 (<1.5).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA21 (5.2%)
- 🔔 Strong above EMA50 (26.4%)
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (59) — BEARISH
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Is BB Stock Still Worth Buying After Its Massive Fiscal 2026 Rally? — Yahoo Finance.
🤖 The article highlights BlackBerry's strong Q1 2027 earnings beat ($153M revenue vs. guidance), doubled EBITDA, and a Zacks Buy rating, supporting a favorable near-term outlook despite high valuation.
✅ BlackBerry Shares Popped Almost 20% After Earnings. BB Stock Is ... — Yahoo Finance.
🤖 Shares jumped 19.95% following the June 25 earnings report, reflecting investor confidence in the company's turnaround and strong fiscal performance.
⚪️ Ahead Of BlackBerry's Q1 Earnings, Stifel Says Market Is Still ... — Yahoo Finance.
🤖 Stifel's pre-earnings commentary notes market skepticism despite expected modest earnings of $0.03/share, presenting a balanced view before the actual positive results were confirmed.
🍭 Bonus (B): 10/10 — Prepackaged Software (Technology sector)

🏢 What they do: Taboola is an advertising technology company that operates a two-sided platform connecting advertisers with audiences across publisher websites and digital properties on the open web, using machine learning to match ads and content recommendations with users .
- 🎯 Current $5.52 is 1% below 3yr high $5.58 · ⏳ SMA200 $3.93 (current price $5.52 is above) · 💰 Market Cap $1.6B
- TBLA shows decent technicals supported by positive sentiment.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 767% (>20%); Low LT D/E 0.07 (<1.0); PEG ratio 0.02 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (8.7%)
- 🔔 Strong above EMA50 (16.7%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 65 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Needham reiterates Taboola stock Buy rating on AI expansion — Investing.com.
🤖 Needham reaffirmed a Buy rating with a $5.50 price target, citing Taboola's strong Q1 2026 earnings beat (EPS of $0.20 vs. expected loss) and its strategic AI expansion, including the DeeperDive monetization engine for generative AI companies.
✅ Taboola stock hits 52-week high at 5.26 USD — Investing.com.
🤖 The stock reached a 52-week high of $5.26, surging 86% from its low, driven by Q1 2026 earnings that significantly exceeded expectations and its upcoming inclusion in the Russell 2000 and 3000 indexes effective June 26, 2026.
✅ Taboola.com (TBLA) Shows Fast-paced Momentum But Is Still a Bargain Stock — Zacks Equity Research.
🤖 Zacks highlights TBLA's fast-paced momentum and notes the stock remains undervalued despite its recent gains, suggesting it is still a bargain opportunity for investors.
🍭 Bonus (B): 10/10 — Computer Programming & Data Processing (Technology sector)

🏢 What they do: Flywire Corporation is a global payments enablement and software company that helps businesses collect and reconcile payments, especially for complex, cross-border transactions. Its platform includes invoice-to-cash automation, payment collection, currency conversion, and ERP/accounting reconciliation for industries like education, healthcare, travel, and B2B.
- 🎯 Current $17.62 is 50% below 3yr high $35.05 · ⏳ SMA200 $13.82 (current price $17.62 is above) · 💰 Market Cap $2.1B
- FLYW shows decent technicals supported by positive sentiment.

💎 Quality (Q): 48/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 433% (>20%); Revenue growth 41% (>15%); Low LT D/E 0.02 (<1.0); PEG ratio 0.17 (<1.5).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA50 (10.3%)
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (57) — BEARISH
📢 Sentiment (S): 6/10
- 🗞️ News sentiment is positive (mixed coverage).
✅ Flywire stock hits 52-week high at 18.07 USD — Investing.com.
🤖 Flywire hit a 52-week high of $18.07, gained over 6% in the past week, and received a price target increase to $22 from Raymond James with an Outperform rating, alongside a JPMorgan upgrade to Neutral, signaling strong investor confidence and growth prospects.
✅ Temasek Holdings Private Ltd Has $90.50 Million Holdings in Flywire Corporation — MarketBeat.
🤖 Temasek Holdings holds $90.50 million in Flywire, and the article notes Flywire reported strong quarterly results with EPS of $0.10 (vs. $0.03 expected) and revenue of $184 million (up 40.9% YoY), reinforcing positive fundamentals.
❌ Flywire (NASDAQ:FLYW) Downgraded to Hold Rating by Wall Street Zen — MarketBeat.
🤖 Wall Street Zen downgraded Flywire from 'buy' to 'hold,' which is a negative signal for the stock, even though the broader analyst consensus remains 'Moderate Buy' with an average price target of $18.07.
⚪️ Flywire general counsel Peter Butterfield sells $561k in stock — Investing.com (ng.investing.com).
🤖 General Counsel Peter Butterfield sold 31,096 shares for ~$561k on July 1, 2026, which is a typical insider transaction; however, the article also highlights Raymond James raising its target to $22 and JPMorgan upgrading the stock, balancing the insider sale with strong analyst optimism.
🍭 Bonus (B): 0/10 — Business Services

🏢 What they do: Bioventus Inc. is a global medical device company that develops and commercializes clinically proven, minimally invasive products to relieve pain and address musculoskeletal challenges by enhancing the body's natural healing process .
- 🎯 Current $11.88 is 13% below 3yr high $13.71 · ⏳ SMA200 $8.37 (current price $11.88 is above) · 💰 Market Cap $799M
- BVS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 43/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 200% (>20%); ROE 15% (>15%); Near-high ROE setup (52wk high + ROE); PEG ratio 0.14 (<1.5).
⏰ Entry (E): 6/20
- 🔔 Strong above EMA21 (14.7%)
- 🔔 Strong above EMA50 (20.8%)
- 🔔 SMA20/SMA50 bullish crossover
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 69 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Wall Street Analysts Predict a 28.81% Upside in Bioventus (BVS) — Yahoo Finance.
🤖 Analysts predict a 28.81% upside for $BVS after the stock gained 24.9% over the past four weeks, closing at $11.49, indicating strong bullish momentum and remaining upside potential.
✅ Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock? — Yahoo Finance.
🤖 The stock surged 12.4% with expectations to post quarterly earnings of $0.21 per share, suggesting positive market reaction and potential for continued growth.
✅ Bioventus: I See A Better Business Trading At A Fair Price (Upgrade) — Seeking Alpha.
🤖 An analyst upgraded $BVS, noting it trades at ~$11.80 below a fair value of $13.04 and a future price target of ~$20, signaling undervaluation and positive long-term prospects.
🍭 Bonus (B): 0/10 — Surgical & Medical Instruments

🏢 What they do: Pitney Bowes is a technology-driven shipping, mailing, and financial services company. It provides tools and services such as postage meters, mailing equipment, shipping software, presort mail services, and parcel/shipping management solutions for businesses of all sizes.
- 🎯 At/above 3yr high $18.33 (current $18.33) · ⏳ SMA200 $12.13 (current price $18.33 is above) · 💰 Market Cap $3.7B
- PBI passed all filters and shows favorable conditions.

💎 Quality (Q): 44/60
- 🏦 Low drawdown (11.9% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 105% (>20%); PEG ratio 0.17 (<1.5).
⏰ Entry (E): 2/20
- 🔔 Strong above EMA21 (6.4%)
- 🔔 Strong above EMA50 (13.5%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 67 showing strength
📢 Sentiment (S): 5/10
- 🗞️ News sentiment is neutral (mixed coverage).
✅ Pitney Bowes (NYSE:PBI) Reaches New 12-Month High — MarketBeat.
🤖 Shares hit a new 52-week high of $18.49, ending the session up 3.6% at $18.4450, reflecting strong momentum and increasingly constructive analyst sentiment.
✅ Hsbc Holdings PLC Increases Stock Position in Pitney Bowes Inc — MarketBeat.
🤖 HSBC Holdings PLC increased its stock position in Pitney Bowes, signaling institutional confidence, while the stock trades near its one-year high of $18.25.
❌ Pitney Bowes CEO Kurt Wolf sells $8.87m in company shares — Investing.com.
🤖 CEO Kurt Wolf sold $8.87 million worth of shares across multiple transactions in early July, which typically signals negative sentiment despite the stock trading near 52-week highs.
❌ Pitney Bowes (NYSE:PBI) CEO Sells 316,280 Shares — MarketBeat.
🤖 CEO Kurt James Wolf sold 316,280 shares on June 12 at an average price of $17.40, representing significant insider selling activity near the stock's 52-week high.
⚪️ Louisiana State Employees Retirement System Purchases Shares of Pitney Bowes Inc — MarketBeat.
🤖 While Louisiana State Employees Retirement System purchased shares, the article notes heavy insider selling by the CEO and a dividend cut, creating mixed signals despite the institutional buy.
🍭 Bonus (B): 0/10 — Office Machines

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 Current $56.50 is 1% below 3yr high $57.10 · ⏳ SMA200 $44.40 (current price $56.50 is above) · 💰 Market Cap $14.3B
- EXEL shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (11.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 44% (>20%); ROE 43% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA50 (10.1%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 64 showing strength
📢 Sentiment (S): 7/10
- 🗞️ News sentiment is positive (mixed coverage).
✅ Truist Financial Raises Exelixis (NASDAQ:EXEL) Price Target to $56.00 — MarketBeat.
🤖 Truist Financial increased its price target on Exelixis from $54 to $56 while maintaining a "Hold" rating, signaling confidence in the stock despite mixed analyst sentiment[9].
✅ UBS raises Exelixis stock price target to $52 on pipeline outlook — Investing.com.
🤖 UBS raised its price target from $43 to $52 while keeping a Neutral rating, citing balanced risk-reward and optimism for zanzalintinib in the upcoming non-clear cell renal cell carcinoma readout[7].
❌ New York State Teachers Retirement System Lowers Position in Exelixis, Inc. $EXEL — MarketBeat.
🤖 The New York State Teachers Retirement System cut its Exelixis stake by 16.3% in Q1, selling 52,415 shares, which may signal institutional caution despite the company's strong Q1 earnings beat[8].
⚪️ Exelixis, Inc. (NASDAQ:EXEL) Given Consensus Recommendation of "Hold" by Analysts — MarketBeat.
🤖 Analysts maintain a "Hold" consensus with 9 buy, 9 hold, and 2 sell ratings, and an average price target of $47.93, despite the company recently beating earnings estimates with EPS of $0.87 versus $0.75 expected[6].
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: A10 Networks is an American public company specializing in application delivery controllers and cybersecurity solutions for on-premises, cloud, and edge environments. The company provides software and hardware products that secure applications, networks, and infrastructure from cyber threats while optimizing performance and availability across hybrid cloud architectures.
- 🎯 Current $37.17 is 2% below 3yr high $38.11 · ⏳ SMA200 $22.35 (current price $37.17 is above) · 💰 Market Cap $2.7B
- ATEN shows decent technicals supported by positive sentiment.

💎 Quality (Q): 44/60
- 🏦 Low drawdown (9.5% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 31% (>20%); ROE 20% (>15%); Low LT D/E 0.99 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (6.1%)
- 🔔 Strong above EMA50 (16.8%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 67 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ A10 Networks (NYSE:ATEN) Sets New 12-Month High - Still a Buy? — MarketBeat.
🤖 The stock hit a new 52-week high of $38.40, driven by strong momentum and a recent earnings beat where EPS of $0.24 exceeded the $0.22 estimate and revenue rose 13.4% year over year[1].
✅ Boston Trust Walden Corp Has $50.25 Million Stake in A10 Networks, Inc. $ATEN — MarketBeat.
🤖 Major institutional investor Boston Trust Walden Corp holds a $50.25 million stake, reinforcing confidence in the company after it beat quarterly expectations and reiterated FY2026 EPS guidance of 0.640-0.650[5].
⚪️ A10 Networks, Inc. $ATEN Shares Sold by Bridge City Capital LLC — MarketBeat.
🤖 While Director Eric Singer sold 24,698 shares, the article notes that several analysts raised targets or ratings, resulting in a consensus 'Moderate Buy' and an average price target of $24.29, balancing the insider sale with positive analyst sentiment[3].
🍭 Bonus (B): 10/10 — Computer Communications Equipment (Technology sector)

🏢 What they do: An out-of-home (OOH) advertising company that owns and operates billboards and transit displays across the United States, providing advertising space and marketing solutions to brands.
- 🎯 Current $33.04 is 2% below 3yr high $33.90 · ⏳ SMA200 $25.82 (current price $33.04 is above) · 💰 Market Cap $5.8B
- OUT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (12.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 179% (>20%); ROE 28% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 7/10
- 🗞️ News sentiment is positive (mixed coverage).
✅ Hsbc Holdings PLC Purchases Shares of 170,438 OUTFRONT Media Inc. OUT — MarketBeat.
🤖 HSBC Holdings PLC opened a new fourth-quarter position buying 170,438 shares valued at ~$4.1 million, signaling institutional confidence in $OUT alongside its 'Moderate Buy' consensus rating and $30.71 price target[1].
✅ Fideuram Intesa Sanpaolo Private Banking S.P.A. Acquires Shares of 72,314 OUTFRONT Media Inc. OUT — MarketBeat.
🤖 Fideuram Intesa Sanpaolo acquired 72,314 shares, reinforcing institutional buying momentum as $OUT reported better-than-expected Q1 earnings ($0.34 EPS) and 10% revenue growth to $429.6 million[5].
❌ Richard H. Sauer, OUTFRONT Media EVP, sells $318121 in shares — Investing.com.
🤖 EVP Richard Sauer sold 10,000 shares for $318,121 on June 23–24, which is negative sentiment despite the company's strong Q1 results; the article notes the stock may be overvalued at a P/E of 29.69 relative to fair value[11].
⚪️ Strs Ohio Sells 59,329 Shares of OUTFRONT Media Inc. $OUT — MarketBeat.
🤖 While STRS Ohio sold 59,329 shares, the article emphasizes that analysts remain generally positive with six Buy ratings and one Hold, and highlights $OUT's strong Q1 EPS beat of $0.34 vs. $0.28 estimate and 3.6% dividend yield[3].
🍭 Bonus (B): 0/10 — REITs

🏢 What they do: Veracyte, Inc. is a leading genomic diagnostics company that provides molecular tests to help clinicians diagnose and guide care for thyroid, prostate, breast, bladder, and lung cancers, enabling patients to avoid risky procedures and accelerate treatment .
- 🎯 Current $56.97 is 6% below 3yr high $60.49 · ⏳ SMA200 $40.06 (current price $56.97 is above) · 💰 Market Cap $4.5B
- VCYT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 48/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 289% (>20%); Revenue growth 21% (>15%); Low LT D/E 0.00 (<1.0); PEG ratio 0.18 (<1.5).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA50 (16.3%)
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (59) — BEARISH
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ Zacks Research Upgrades Veracyte (NASDAQ:VCYT) to Strong-Buy — MarketBeat.
🤖 Zacks Research upgraded Veracyte from Hold to Strong-Buy, reinforcing a generally positive analyst backdrop and contributing to a consensus rating of Moderate Buy with a $50.43 price target.
✅ All You Need to Know About Veracyte (VCYT) Rating Upgrade to ... — Yahoo Finance.
🤖 Veracyte was upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects and strengthening its investment appeal.
⚪️ Veracyte, Inc. (NASDAQ:VCYT) Receives Consensus Rating of Moderate Buy from Brokerages — MarketBeat.
🤖 Nine brokerages maintain a 'Moderate Buy' consensus with a $50.43 average price target, though the article notes recent insider sales totaling over $10 million, adding a cautionary element despite solid earnings beats.
⚪️ Granite Investment Partners LLC Trims Position in Veracyte, Inc ... — MarketBeat.
🤖 Granite Investment Partners reduced its Veracyte position, but the article highlights the company's strong Q1 earnings beat ($0.52 EPS vs $0.34 estimate) and a 'Moderate Buy' consensus with a $50.43 target, balancing the trim with positive fundamentals.
🍭 Bonus (B): 0/10 — Medical Laboratories

🏢 What they do: Pediatrix Medical Group, Inc. (ticker: MD) is one of the nation's largest providers of physician-led prenatal, neonatal, maternal-fetal, and pediatric subspecialty services. The company partners with nearly 400 hospitals across 36 states, staffing NICUs and delivering coordinated, evidence-based care to women, babies, and children through a network of over 4,400 affiliated clinicians.
- 🎯 Current $26.27 is 4% below 3yr high $27.39 · ⏳ SMA200 $21.32 (current price $26.27 is above) · 💰 Market Cap $2.2B
- MD shows decent technicals supported by positive sentiment.

💎 Quality (Q): 51/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 50% (>20%); ROE 20% (>15%); Low LT D/E 0.70 (<1.0); Near-high ROE setup (52wk high + ROE).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA50 (10.1%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 64 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Burney Co. Makes New $1.13 Million Investment in Pediatrix Medical Group Inc (MD) — MarketBeat.
🤖 Burney Co.'s new $1.13 million investment signals institutional confidence in $MD, which is a positive catalyst for the stock price despite analysts maintaining a consensus Hold rating.
✅ Pediatrix Medical Group stock hits 52-week high at 25.02 USD — Investing.com.
🤖 The stock reached a 52-week high of $25.02 and reported Q1 2026 earnings of $0.44 EPS, beating estimates by 15.79%, which is a strong positive indicator for the stock.
✅ Pediatrix Medical Group (MD) is a Top-Ranked Growth Stock — Zacks Equity Research.
🤖 Zacks ranks MD as a #2 (Buy) with a VGM Score of A and forecasts 9.3% year-over-year earnings growth, suggesting the stock is a strong growth opportunity for investors.
🍭 Bonus (B): 0/10 — Hospitals